Abstract 5605
Background
Staff who comes in contact with cytotoxic agents in conjunctions with preparation, administration, nursing care and cleaning are at risk for exposure. These hazardous drugs can alter DNA or affect other intracellular processes that interfere with cancer cell growth. Using personal protection equipment (PPE) and closed systems reduce but doesn’t eliminate the risks of exposure. Current guidelines vary between countries and few organization test exposure risks systematically.
Methods
We performed tests on occupational exposure (from 10 different health care surfaces) from three types of chemotherapy (Cyclophosphamide, Gemcitabine and Fluorouracil) from three different hospitals in Sweden. The tests were analyzed at an accredited lab according to protocol. We also collected survey data from cancer nurses on safety awareness, adherence to safety protocol and education from the same hospitals. Data on cleaning routines were also collected.
Results
Preliminary results showed exposure above recommended risk level at all three hospitals and for all three drugs. The survey data showed that nurses only partly follow the recommended PPE but all responded that they had knowledge and competence to handle cytotoxic drugs, even if 37 % reported not to receiving any education from the employer. Cleaning routines differed between the hospitals and may explain some of the exposures.
Conclusions
Nurses in chemotherapy care are exposed to cytotoxic drugs. Efforts are needed to reduce these occupational risks and managers need to adopt a systematic approach to test exposure risks and to intervene. Guidelines need to be revised and include recent research results. Clinical nurses should always use PPE.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Regionalt cancercentrum Stockholm-Gotland.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1885 - Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: an open label, non randomized study
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
5259 - Integrative RNAseq and Target panel sequencing reveals common and distinct innate and adaptive resistance mechanisms to BRAF inhibitors
Presenter: Phil Cheng
Session: Poster Display session 3
Resources:
Abstract
5619 - Effective treatment with T-VEC monotherapy in Stage IIIB/C-IVM1a Melanoma of the Head & Neck Region
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
5666 - Re-introduction of T-VEC Monotherapy in Recurrent Stage IIIB/C-IVM1a melanoma is effective
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
4117 - Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): subgroup analysis of the phase 3 OPTiM study
Presenter: Mark Middleton
Session: Poster Display session 3
Resources:
Abstract
5303 - Real Life Use of Talimogene Laherparepvec in Melanoma in Centers in Austria and Switzeland
Presenter: Christoph Hoeller
Session: Poster Display session 3
Resources:
Abstract
4130 - Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP)
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
2050 - Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)
Presenter: Sarah Knispel
Session: Poster Display session 3
Resources:
Abstract
1618 - Comparative-Effectiveness of Pembrolizumab vs. Nivolumab for Patients with Metastatic Melanoma
Presenter: Justin Moser
Session: Poster Display session 3
Resources:
Abstract
3556 - Long-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: a network meta-analysis
Presenter: Peter Mohr
Session: Poster Display session 3
Resources:
Abstract